Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
- Referrals to patient-related programs or resources
- Donations, website, or event-related assistance
- Tobacco-related topics
- Volunteer opportunities
- Cancer Information
For medical questions, we encourage you to review our information with your doctor.
Acute Myeloid Leukemia (AML) in Adults
- Chemotherapy for Acute Myeloid Leukemia (AML)
- Targeted Therapy Drugs for Acute Myeloid Leukemia (AML)
- Non-Chemo Drugs for Acute Promyelocytic Leukemia (APL)
- Surgery for Acute Myeloid Leukemia (AML)
- Radiation Therapy for Acute Myeloid Leukemia (AML)
- Stem Cell Transplant for Acute Myeloid Leukemia (AML)
- Typical Treatment of Acute Myeloid Leukemia (Except APL)
- Treatment of Acute Promyelocytic Leukemia (APL)
- Treatment Response Rates for Acute Myeloid Leukemia (AML)
- If Acute Myeloid Leukemia (AML) Doesn’t Respond or Comes Back After Treatment
- If You Have Acute Myeloid Leukemia (AML)
Non-Chemo Drugs for Acute Promyelocytic Leukemia (APL)
The main medicines used to treat acute promyelocytic leukemia (APL) are different from those used to treat other types of acute myeloid leukemia (AML).
Chemotherapy (chemo) is the main treatment for most types of acute myeloid leukemia (AML). But acute promyelocytic leukemia (APL) is different from other types of AML in some important ways.
The leukemia cells in APL (called blasts) aren't able to mature into normal white blood cells, and they can grow and divide very quickly. These cells contain proteins that when released into the bloodstream can cause out-of-control blood clotting. This can lead to problems not only with blood clots, but also with severe bleeding. In the past, when standard chemo drugs were used alone to kill APL cells, these proteins were released into the bloodstream, and some people died from clotting or bleeding complications.
Researchers have found that the leukemia cells in APL have a specific gene change that makes them sensitive to certain drugs that aren’t like standard chemo drugs. These drugs help the blasts mature into normal white blood cells. This process is known as differentiation,and these drugs are called differentiation agents. Since the blasts don’t die, they don’t release the harmful proteins into the blood, which helps keep the clotting process from getting out of control. But these drugs can also have side effects of their own.
Two of these drugs can be used to treat APL:
- All-trans-retinoic acid (ATRA, tretinoin, or Vesanoid)
- Arsenic trioxide (ATO, Trisenox)
For more on how these drugs are used for APL, see Treatment of Acute Promyelocytic Leukemia (APL).
All trans-retinoic acid (ATRA)
ATRA is a medicine related to vitamin A. It is typically part of the initial (induction) treatment of APL, either along with chemo, or along with arsenic trioxide (see below). It is also often used for some time after as part of the consolidation phase of treatment to help keep the leukemia from coming back. For this phase of treatment, it may be used with chemo or with arsenic trioxide (or possibly with both). For longer-term maintenance, ATRA might be used by itself or with chemo.
ATRA can have side effects similar to those seen if you take too much vitamin A. Symptoms can include headache, fever, dry skin and mouth, skin rash, swollen feet, sores in the mouth or throat, itching, and irritated eyes. It can also cause blood lipid levels (like cholesterol and triglycerides) to go up. Often liver blood test results become abnormal. These side effects often go away when the drug is stopped.
Arsenic trioxide (ATO)
Arsenic trioxide (ATO) can act in a way similar to ATRA in patients with APL. It can be given with ATRA in the induction and consolidation phases of treatment, but it is also helpful in treating people whose APL comes back after treatment with ATRA plus chemo. In these people, ATO might be given along with ATRA and/or the targeted drug gemtuzumab ozogamicin (Mylotarg).
Side effects of ATO can include fatigue (tiredness), nausea, vomiting, diarrhea, abdominal (belly) pain, and nerve damage (called neuropathy) leading to numbness and tingling in the hands and feet. ATO can also cause problems with heart rhythm, which can be serious. Your doctor may check your heart rhythm with an EKG often (even daily) while you are getting this drug.
Differentiation syndrome
The most important side effect of either of these drugs is known as differentiation syndrome (previously called retinoic acid syndrome). This occurs when the leukemia cells release certain chemicals into the blood. It is most often seen during the first couple of weeks of treatment, and in people with a high white blood cell count.
Symptoms can include fever, breathing problems due to fluid buildup in the lungs and around the heart, low blood pressure, kidney damage, and severe fluid buildup elsewhere in the body. While differentiation syndrome can be serious, it can often be treated by stopping the drugs for a while and giving a steroid such as dexamethasone.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Appelbaum FR. Chapter 95: Acute leukemias in adults. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa. Elsevier: 2020.
Larson RA. Initial treatment of acute promyelocytic leukemia in adults. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/initial-treatment-of-acute-promyelocytic-leukemia-in-adults on June 4, 2024.
Larson RA. Treatment of relapsed or refractory acute promyelocytic leukemia in adults. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/treatment-of-relapsed-or-refractory-acute-promyelocytic-leukemia-in-adults on June 4, 2024.
National Cancer Institute. Acute Myeloid Leukemia Treatment (PDQ)–Health Professional Version. 2024. Accessed at https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq on June 3, 2024.
National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology (NCCN Guidelines): Acute Myeloid Leukemia. V.3.2024. Accessed at https://www.nccn.org on June 3, 2024.
Last Revised: June 5, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.